# Molecular Partners

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/molecular-partners

- Industry: Biotechnology
- Headquarters: Zurich, Switzerland
- Website: www.molecularpartners.com
- Total disclosed funding: $61M
- Latest round: Series B (Dec 15, 2009)
- Investors on record: 5

## About

Based in Switzerland, Molecular Partners is a biotechnology company focused on developing innovative DARPin therapeutics for cancer treatment, enhancing potential outcomes for patients with challenging oncological conditions.Molecular Partners AG specializes in biopharmaceuticals, primarily working with DARPin technology to create targeted therapies. Founded in Zurich, Switzerland in 2004 by Kaspar Binz, the company has completed six deals, with its most recent funding round, a Private Placement/Follow on, raising USD 63.75 mn on June 16, 2021. The total amount raised by the company amounts to USD 63.75 mn.Molecular Partners specializes in pioneering DARPin (Designed Ankyrin Repeat Protein) therapeutics aimed at providing innovative solutions for cancer treatment. Their core product offerings include a range of tetra-specific T cell engagers that target multiple cancer-specific antigens, such as CD33, CD123, and CD70, in conjunction with CD3 to enhance T cell activity against tumors. The company also features a lead program targeting DLL3, as well as a logic-gated platform designed for the targeted and conditional activation of immune cells. These products are designed to address critical unmet needs in oncology, particularly for patients with forms of cancer that are resistant to conventional therapies. Molecular Partners has positioned its offerings for markets including North America and Europe, aiming to serve a diverse client base that includes healthcare providers, oncology specialists, and research institutions focused on advanced cancer treatments.Molecular Partners generated revenue of USD 7,837,902.50 in 2023, with an EBITDA of -USD 65,358,173.10 for the same year. The company generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies and research institutions that seek to leverage its proprietary DARPin technology for drug development. Transaction structures typically involve joint development agreements, where partners finance research and clinical trials in exchange for access to specific therapeutic candidates. Revenue may also be derived from milestone payments linked to the achievement of regulatory approvals or sales targets, as well as royalties on commercialized products. The focus on collaborations suggests a business model emphasizing B2B relationships, providing tailored therapeutics to oncology-focused enterprises. The company’s innovative products, including its tetra-specific T cell engagers and multi-specific DARPin therapeutics, are integral to its revenue generation strategy as they advance through clinical trials and into potential commercialization.Molecular Partners plans to continue its growth trajectory by launching new products designed around its DARPin technology. Specific timelines for product launches have not been disclosed. The company aims to expand its market presence in North America and Europe, leveraging its recent funding of USD 63.75 mn from the public offering in June 2021 to support these initiatives. This funding will likely facilitate further research and development efforts as well as potential market access strategies.

## Funding rounds

- Series B, Dec 15, 2009, $46M — Essex Woodlands, Index Ventures, Johnson & Johnson Innovation, BB Biotech, Endeavour Vision
- Series A, Aug 14, 2007, $15M — Index Ventures, Johnson & Johnson Innovation, BB Biotech, Endeavour Vision

## Investors

- Index Ventures (https://capitalatlas.ai/funds/index-ventures) — Series A, Series B
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A, Series B
- BB Biotech (https://capitalatlas.ai/funds/bb-biotech) — Series A, Series B
- Endeavour Vision (https://capitalatlas.ai/funds/endeavour-vision) — Series A, Series B
- Essex Woodlands (https://capitalatlas.ai/funds/essex-woodlands) — Series B